Cystic Fibrosis bacterioPHage study at Yale (CYPHY) (NACFC 2023) - Jul 27, 2023 - Abstract #W30.1; 41; Pres time: Nov 4, 2023; 07:15 AM - 09:15 AM; Location: 213 B (West); "The study drug was Yale Phage Therapy 01 (YPT-01), a nebulized single-phage therapy determined for each subject using an algorithm that selects the best-performing phage from among three candidate phages depending on baseline susceptibility testing... MDR P. aeruginosa is increasingly common in CF and exceedingly difficult to manage. Therefore, development of novel thera-peutic approaches that reduce infection with minimal side-effects are highly desirable to the CF community. In this first-in-human inhaled phage–therapy clinical trial, there was no difference in bacterial titers, but inhaled phage therapy was shown to be safe."
Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases
|
|
B. Chan1; K. Kortright1; G. Stanley2; C. Cochrane2; A. Lee1; A. Vill3; Y. Sun2; J. Stewart4; C. Britto-Leon2; Z. Harris2; J. Talkwalkar5; V. Shabanova6; P. Turner7; J. Koff5
|